List view / Grid view
NRG Therapeutics to develop small molecule disease-modifying medicines for debilitating chronic neurodegenerative disorders
NRG is developing a pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with potential as first-in-class treatments for Parkinson's disease and motor neuron disease.
Scientists have synthesised a new molecule that could kill a broad spectrum of hard-to-treat cancers, including triple-negative breast cancer, by exploiting a weakness in cells not previously targeted by other drugs.
Here Bio-Rad presents the generation of specific anti-CAR T-cell antibodies to show how CAR T-cell analysis benefits from our modular antibody assembly technology using SpyTag-SpyCatcher protein ligation.
9 May 2022 | By PerkinElmer and C4
Looking for a way to address the undruggable proteins in the human body? Watch this free on-demand webinar where industry experts discuss strategies to accelerate TPD drug discovery efforts using high-throughput cell-based assays.
6 May 2022 | By Eurofins Discovery
Sign up for our free live webinar to learn how to accelerate screening and Structure Activity Relationship (SAR) analysis in the targeted protein degradation (TPD) drug discovery field.
An efficient and effective PIM3 kinase-focused screening cascade for identification of multiple novel and tractable hit series
14 April 2022 | By Eurofins Discovery Services
Watch this free on-demand webinar to understand how to rapidly identify selective, specific, potent and tractable hit series with appropriate ADME characteristics to speed up hit-to-lead.
A review of current challenges and goals in cardiac drug discovery and how innovations on human iPSC technology are helping to overcome them.
timsTOF MALDI PharmaPulse, a trapped ion mobility-enabled mass spec solution for label-free HTS in drug discovery
25 March 2022 | By Bruker Daltonics
Watch our free on-demand webinar to discover how the new timsTOF MPP product solution, with its dedicated MALDI PharmaPulse 2023 HTS software suite, improves data quality and accelerates high-throughput screening in drug discovery.
Novel research has shown that morphological fingerprinting could help identify side effects of new bioactive compounds in drug discovery.
A recent pre-clinical study from Washington University School of Medicine showed that a new class of compounds can potentially improve multiple aspects of metabolic syndrome, including diabetes.
Sanofi and Exscientia will develop up to 15 novel drug candidates by leveraging the latter's AI discovery and optimisation platform.
Benefits and key considerations of using human iPSC-derived disease models in drug discovery.
Episode 5 – Small molecule screening with Dr Sheraz Gul, Fraunhofer Institute & Dr John Fuller, Beckman Coulter
In this latest episode, we discuss how small molecule discovery can be automated and how this process saves researchers time and money.